US FDA to remove unproven, potentially harmful treatment used in ‘stem cell’ centers – Times of India
|
US FDA to remove unproven, potentially harmful treatment used in ‘stem cell‘ centers
Times of India Fda-Seizure comes after fda inspections at stemimmune, california stem cell treatment centers confirmed vaccine used to create an unapproved stem cell product. * Fda says u.s. Department of justice filed seizure complaint, on behalf of fda, in u.s … |
|
Statement from FDA Commissioner Scott Gottlieb, MD on the FDA’s new policy steps and enforcement efforts to ensure …
FDA.gov Recent advances in our basic knowledge of the pathways involved in tissue damage and regeneration have combined with remarkable progress in adult stem cell biology to put us at a genuine inflection point in the history of medicine. The prospect of … |
|
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
PR Newswire (press release) The acquisition will provide CSL Behring with Calimmune’s pre-clinical asset, CAL-H, an HSC gene therapy for the treatment of sickle cell disease and β-thalassemia, which complements CSL Behring’s current product portfolio and deep expertise in … |
|
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
Benzinga VBI-1901 is a novel immunotherapy developed using VBI’s eVLP technology to target CMV-positive (CMV+) tumors, including glioblastoma multiforme (GBM), the company’s lead immuno-oncology program. Dr. Anderson will present data in animal models … |
|
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
Marketwired (press release) VBI-1901 is a novel immunotherapy developed using VBI’s eVLP technology to target CMV-positive (CMV+) tumors, including glioblastoma multiforme (GBM), the company’s lead immuno-oncology program. Dr. Anderson will present data in animal models … |
Markets Insider |
Gilead just bought a cancer-immunotherapy company for $12 billion
Markets Insider Gilead, known for its HIV and hepatitis C drugs, has been growing a cash pile over the past few years since the approval of its hepatitis C drug in 2013, leading investors to speculate what company it might buy. Gilead’s purchase of Kite is the first … Kite Soars on Sale to Gilead – Biotech MoversTheStreet.com Gilead Makes Long-Awaited Splash With $12B Bet on Kite, Cell TherapyXconomy Gilead is buying Santa Monica biotech firm Kite Pharma for $11.9 billionLos Angeles Times STLtoday.com –Proactive Investors UK all 162 news articles » |